Role of thalidomide in previously untreated patients with multiple myeloma

Pellegrino Musto; Fiorella D'Auria; Giuseppe Pietrantuono; Sara Bringhen; Fortunato Morabito; Francesco Di Raimondo; Samantha Pozzi; Stefano Sacchi; Mario Boccadoro; Antonio Palumbo

doi:10.1586/14737140.8.10.1569

Role of thalidomide in previously untreated patients with multiple myeloma

Pellegrino Musto, Fiorella D'Auria, Giuseppe Pietrantuono, Sara Bringhen, Fortunato Morabito, Francesco Di Raimondo, Samantha Pozzi, Stefano Sacchi, Mario Boccadoro, Antonio Palumbo

IRCCS Centro di Riferimento Oncologico della Basilicata (CROB)

Research output: Contribution to journal › Article › peer-review

Abstract

Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years. Despite some toxicities, it has demonstrated significant efficacy in elderly patients, as well as in the setting of younger subjects receiving autologous stem cell transplantation. Here, we report and discuss the clinical results achieved with thalidomide alone or in combination with dexamethasone or other drugs, such as melphalan, cyclophosphamide, doxorubicin and bortezomib, in previously untreated myeloma patients.

Original language	English
Pages (from-to)	1569-1580
Number of pages	12
Journal	Expert Review of Anticancer Therapy
Volume	8
Issue number	10
DOIs	https://doi.org/10.1586/14737140.8.10.1569
Publication status	Published - 2008

Keywords

Bortezomib
Cyclophosphamide
Dexamethasone
Doxorubicin
First-line therapy
Lenalidomide
Melphalan
Myeloma
Peripheral neuropathy
Thalidomide
Thrombosis

ASJC Scopus subject areas

Pharmacology (medical)
Oncology

Access to Document

10.1586/14737140.8.10.1569

Fingerprint Dive into the research topics of 'Role of thalidomide in previously untreated patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this

Role of thalidomide in previously untreated patients with multiple myeloma. / Musto, Pellegrino; D'Auria, Fiorella ; Pietrantuono, Giuseppe; Bringhen, Sara; Morabito, Fortunato; Di Raimondo, Francesco; Pozzi, Samantha; Sacchi, Stefano; Boccadoro, Mario; Palumbo, Antonio.

In: Expert Review of Anticancer Therapy, Vol. 8, No. 10, 2008, p. 1569-1580.

Research output: Contribution to journal › Article › peer-review

@article{21dce8d00b754660b4dd635f82fe4242,

title = "Role of thalidomide in previously untreated patients with multiple myeloma",

abstract = "Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years. Despite some toxicities, it has demonstrated significant efficacy in elderly patients, as well as in the setting of younger subjects receiving autologous stem cell transplantation. Here, we report and discuss the clinical results achieved with thalidomide alone or in combination with dexamethasone or other drugs, such as melphalan, cyclophosphamide, doxorubicin and bortezomib, in previously untreated myeloma patients.",

keywords = "Bortezomib, Cyclophosphamide, Dexamethasone, Doxorubicin, First-line therapy, Lenalidomide, Melphalan, Myeloma, Peripheral neuropathy, Thalidomide, Thrombosis",

author = "Pellegrino Musto and Fiorella D'Auria and Giuseppe Pietrantuono and Sara Bringhen and Fortunato Morabito and {Di Raimondo}, Francesco and Samantha Pozzi and Stefano Sacchi and Mario Boccadoro and Antonio Palumbo",

year = "2008",

doi = "10.1586/14737140.8.10.1569",

language = "English",

volume = "8",

pages = "1569--1580",

journal = "Expert Review of Molecular Diagnostics",

issn = "1473-7159",

publisher = "Expert Reviews Ltd.",

number = "10",

}

TY - JOUR

T1 - Role of thalidomide in previously untreated patients with multiple myeloma

AU - Musto, Pellegrino

AU - D'Auria, Fiorella

AU - Pietrantuono, Giuseppe

AU - Bringhen, Sara

AU - Morabito, Fortunato

AU - Di Raimondo, Francesco

AU - Pozzi, Samantha

AU - Sacchi, Stefano

AU - Boccadoro, Mario

AU - Palumbo, Antonio

PY - 2008

Y1 - 2008

N2 - Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years. Despite some toxicities, it has demonstrated significant efficacy in elderly patients, as well as in the setting of younger subjects receiving autologous stem cell transplantation. Here, we report and discuss the clinical results achieved with thalidomide alone or in combination with dexamethasone or other drugs, such as melphalan, cyclophosphamide, doxorubicin and bortezomib, in previously untreated myeloma patients.

AB - Thalidomide represents one of the most relevant therapeutic advances for patients with multiple myeloma over the last 10 years. Despite some toxicities, it has demonstrated significant efficacy in elderly patients, as well as in the setting of younger subjects receiving autologous stem cell transplantation. Here, we report and discuss the clinical results achieved with thalidomide alone or in combination with dexamethasone or other drugs, such as melphalan, cyclophosphamide, doxorubicin and bortezomib, in previously untreated myeloma patients.

KW - Bortezomib

KW - Cyclophosphamide

KW - Dexamethasone

KW - Doxorubicin

KW - First-line therapy

KW - Lenalidomide

KW - Melphalan

KW - Myeloma

KW - Peripheral neuropathy

KW - Thalidomide

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=55249087667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249087667&partnerID=8YFLogxK

U2 - 10.1586/14737140.8.10.1569

DO - 10.1586/14737140.8.10.1569

M3 - Article

C2 - 18925849

AN - SCOPUS:55249087667

VL - 8

SP - 1569

EP - 1580

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 10

ER -